Lung Cancer
Advertisement
Deborah Brown shares key findings from the recently released seventh annual "State of Lung Cancer" report.
Researchers Analyze Olaparib, Pemetrexed as Maintenance Therapy Additions to Pembrolizumab for NSCLC
Pembrolizumab plus maintenance olaparib was not shown to improve survival in patients with metastatic nonsquamous NSCLC.
The campaign kicked off on November 1 to coincide with Lung Cancer Awareness Month.
Durvalumab does not improve overall survival compared to chemotherapy when used as a first-line treatment for mNSCLC.
The updated analysis was presented at the Society for Immunotherapy in Cancer 2024 Annual Meeting.
Deborah Brown shares how the American Lung Association and its LUNG FORCE initiative are raising awareness this month.
Officials Provide Update on Datopotamab Deruxtecan Biologics License Application for NSCLC Treatment
A prior BLA has been voluntarily withdrawn and a new BLA has been submitted for US accelerated approval.
The real-world study is the first to provide an overview of EGFR mutations and subtype prevalence in patients with NSCLC.
Dr. Studts discusses why Lung Cancer Awareness Month is a critical time to inspire action, engagement, and hope.
The research, presented at SITC 2024, showed the deep learning approach could help predict ICI response in NSCLC.
The initiative is promoting lung cancer screening and efforts to fund research, as well as releasing an upcoming report.
Researchers conducted an extensive analysis of PM2.5 exposure based on residential history, satellite data, and more.
For patients with inoperable stage III NSCLC, ctDNA is associated with survival outcomes of consolidation immunotherapy.
Lung Cancer Awareness Month is observed every November and represents a key time to take action and raise awareness.
The campaign, titled "Anyone with Lungs Can Get Lung Cancer," includes multiple virtual and in-person components.
The study is evaluating the combination as an adjuvant treatment for certain patients with resectable NSCLC.
Arthi Sridhar, MD, discusses the real-world study, which was presented at the IASLC 2024 World Conference on Lung Cancer.
Learn what the global survey showed about the rates of biomarker testing and the remaining barriers to implementation.
Michael R. Gieske, MD, discusses the lung cancer screening initiative, which has been recognized on a national level.
The three-year survival rate in the 2020 cohort of patients with NSCLC was more than double that of the 2000 cohort.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.